14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
RCUS vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). RCUS carries a Unified Composite Score of 48.4/100 (HOLD) at $16.97 (N/M Forward P/E, -475.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While RCUS currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -475.0% operating margin) and revenue trajectory (-7.9% vs. -65.4% YoY).
Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ RCUS vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Arcus Biosciences, Inc. (RCUS) in the Tradestie Institutional Equity Comparison Engine, winning 6–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). RCUS carries a Unified Composite Score of 48.4/100 (HOLD) at $16.97 (N/M Forward P/E, -475.0% operating margin), whereas CAPR carries 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RCUS currently prints a higher short-term Unified Composite Score (48.4/100 HOLD vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (6–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -475.0% operating margin) and revenue trajectory (-7.9% vs. -65.4% YoY). Technical & Structure Timing Caution: RCUS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 33.3); meanwhile CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
RCUS leads the Growth & Scale pillar: RCUS posts -65.4% YoY revenue growth and +0.0% YoY earnings growth on $100M TTM revenue (N/A gross margin, -475.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RCUS cumulative revenue shifted +200.0% while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, RCUS deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
CAPR screens cheaper on headline valuation multiples. RCUS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 25.2x EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RCUS (-114.1% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, RCUS carries 43.1% implied volatility (1st %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.56β · 90% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.